Maribavir

Maribavir is a prescription medication used for the treatment of Cytomegalovirus Infection. 

• Maribavir is available under the following different brand names: Livtencity.

Common side effects of Maribavir include:

• Nausea, 
• Vomiting, 
• Diarrhea, 
• Fatigue, and 
• Loss of taste

Serious side effects of Maribavir include:

• Hives, 
• Difficulty breathing, 
• Swelling of the face, lips, tongue, or throat, and
• Severe dizziness

Rare side effects of Maribavir include:

• None 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out. 

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult and pediatric dosage

Tablet

• 200 mg

Cytomegalovirus Infection

Adult and pediatric dosage

• 400 mg orally two times a day with or without food

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Maribavir has no noted severe interactions with any other drugs.
• Maribavir has no noted serious interactions with any other drugs.
• Maribavir has no noted moderate interactions with any other drugs.
• Maribavir has no noted minor interactions with any other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, health questions, or concerns.

Contraindications

• None

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Maribavir?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Maribavir?”

Cautions

• Virologic failure during treatment and relapse post-treatment
• Virologic failure due to resistance can occur during and after treatment.
• Virologic relapse during the posttreatment period usually occurred within 4-8 weeks after treatment discontinuation.
• Monitor CMV DNA levels and check for maribavir resistance if nonresponsive to treatment or relapses occur.
• Drug interaction overview
  • Substrate of CYP3A4; weak inhibitor of CYP3A4, P-gp, and BCRP
  • Strong CYP3A4 inducers (anticonvulsants)
    • Increase maribavir dose.
    • Strong CYP3A4 inducers (. g, phenytoin, phenobarbital, carbamazepine) decrease maribavir plasma concentration and may result in a reduced virologic response.
  • Strong CYP3A4 inducers (other)
    • Not recommended
  • Strong CYP3A4 inducers (.g, rifabutin, rifampin, St. John’s wort) decrease maribavir plasma concentration and may result in reduced virologic response
  • Valganciclovir and ganciclovir
    • Not recommended
    • Maribavir may antagonize the antiviral activity of ganciclovir and valganciclovir by inhibiting human CMV pUL97 kinase, which is required for the activation/phosphorylation of ganciclovir and valganciclovir.
  • Immunosuppressants
    • Frequently monitor immunosuppressant drug levels during treatment, especially following initiation and after discontinuation, and adjust the immunosuppressant dose, as needed.
    • Maribavir may increase concentrations of immunosuppressive drugs that are CYP3A4 and P-gp substrates (.g, tacrolimus, everolimus, sirolimus, cyclosporine) where minimal concentration changes may lead to serious adverse effects
  • Digoxin
    • Use with caution; monitor digoxin levels; digoxin dose may need to be reduced.
    • Maribavir may increase digoxin levels by inhibiting P-gp.
  • Rosuvastatin
    • Closely monitor for rosuvastatin-related events (. g, myopathy, rhabdomyolysis)
    • Maribavir may increase rosuvastatin levels.

Pregnancy and Lactation

• No adequate human data are available to establish drug-related risks to pregnancy outcomes.
• Lactation
  • Unknown whether maribavir or its metabolites are present in human or animal milk, its effects on milk production, or its effect on breastfed infants.